Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
Conditions
Non-Small Cell Lung Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Beijing Chest Hospital, Beijing, Beijing Municipality, China
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
Harbin Cancer Hospital, Harbin, Heilongjiang, China
Hunan Cancer Hospital, Changsha, Hunan, China
Jiangsu People's Hospital, Nanjing, Jiangsu, China
Nanjing Gulou Hospital, Nanjing, Jiangsu, China
The First Hospital of Jilin University, Changchun, Jilin, China
First Affilicated Hospital of China Medical University, Shengyang, Liaoning, China
Shandong Cancer Hospital, Jinan, Shandong, China
Shanghai Chest Hospital, Shanghai, Shanghai Municipality, China
The First Affilicated Hospital of Xi'An Jiaotong University, Xi’an, Shanxi, China
Sichuan Cancer Hospital, Chengdu, Sichuan, China
West China Hospital, Sichuan University, Chengdu, Sichuan, China
Tianjin Cancer Hospital, Tianjin, Tianjin Municipality, China
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Hangzhou Cancer Hospital, Hangzhou, Zhejiang, China
Zhejiang Taizhou Hospital, Taizhou, Zhejiang, China